Ariad Pharmaceuticals Inc. (ARIA) Reaches New 12-Month High at $10.36
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) reached a new 52-week high during trading on Thursday . The company traded as high as $10.36 and last traded at $10.18, with a volume of 3,429,297 shares traded. The stock had previously closed at $9.97.
A number of equities research analysts have recently commented on ARIA shares. Cowen and Company reaffirmed an “outperform” rating and set a $10.00 price target on shares of Ariad Pharmaceuticals in a research report on Sunday, July 31st. Jefferies Group reaffirmed a “buy” rating and set a $13.00 price target on shares of Ariad Pharmaceuticals in a research report on Wednesday, June 22nd. JMP Securities reaffirmed a “buy” rating on shares of Ariad Pharmaceuticals in a research report on Monday, June 6th. Royal Bank Of Canada reaffirmed a “hold” rating on shares of Ariad Pharmaceuticals in a research report on Monday, June 20th. Finally, William Blair reaffirmed a “buy” rating and set a $10.00 price target on shares of Ariad Pharmaceuticals in a research report on Tuesday, May 24th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $9.19.
The company’s market cap is $2.04 billion. The firm has a 50-day moving average of $8.31 and a 200-day moving average of $7.10.
Ariad Pharmaceuticals (NASDAQ:ARIA) last announced its earnings results on Thursday, July 28th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.70. The business had revenue of $65.30 million for the quarter, compared to the consensus estimate of $60.64 million. During the same quarter in the previous year, the company earned ($0.28) EPS. The firm’s revenue for the quarter was up 133.0% on a year-over-year basis. On average, equities research analysts forecast that Ariad Pharmaceuticals Inc. will post ($0.08) earnings per share for the current fiscal year.
In related news, Director Massimo Radaelli sold 108,569 shares of the stock in a transaction that occurred on Tuesday, June 14th. The stock was sold at an average price of $8.25, for a total transaction of $895,694.25. Following the completion of the sale, the director now directly owns 128,088 shares of the company’s stock, valued at $1,056,726. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Timothy P. Clackson sold 17,762 shares of the stock in a transaction that occurred on Monday, May 23rd. The shares were sold at an average price of $8.08, for a total value of $143,516.96. Following the sale, the insider now directly owns 288,741 shares of the company’s stock, valued at $2,333,027.28. The disclosure for this sale can be found here.
An institutional investor recently raised its position in Ariad Pharmaceuticals stock. Rhumbline Advisers boosted its position in Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) by 7.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 174,193 shares of the pharmaceutical company’s stock after buying an additional 12,560 shares during the period. Rhumbline Advisers owned 0.09% of Ariad Pharmaceuticals worth $1,089,000 as of its most recent SEC filing.
ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.